- Home
- JGH vs AMRN Comparison
JGH vs AMRN Comparison
Compare JGH & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JGH
- AMRN
- Stock Information
- Founded
- JGH 2014
- AMRN 1989
- Country
- JGH United States
- AMRN Ireland
- Employees
- JGH N/A
- AMRN N/A
- Industry
- JGH Investment Managers
- AMRN Biotechnology: Pharmaceutical Preparations
- Sector
- JGH Finance
- AMRN Health Care
- Exchange
- JGH Nasdaq
- AMRN Nasdaq
- Market Cap
- JGH 306.4M
- AMRN 338.7M
- IPO Year
- JGH N/A
- AMRN 1993
- Fundamental
- Price
- JGH $12.70
- AMRN $15.71
- Analyst Decision
- JGH
- AMRN Strong Sell
- Analyst Count
- JGH 0
- AMRN 1
- Target Price
- JGH N/A
- AMRN $12.00
- AVG Volume (30 Days)
- JGH 73.9K
- AMRN 147.4K
- Earning Date
- JGH 01-01-0001
- AMRN 10-29-2025
- Dividend Yield
- JGH 9.85%
- AMRN N/A
- EPS Growth
- JGH N/A
- AMRN N/A
- EPS
- JGH N/A
- AMRN N/A
- Revenue
- JGH N/A
- AMRN $226,733,000.00
- Revenue This Year
- JGH N/A
- AMRN N/A
- Revenue Next Year
- JGH N/A
- AMRN N/A
- P/E Ratio
- JGH N/A
- AMRN N/A
- Revenue Growth
- JGH N/A
- AMRN N/A
- 52 Week Low
- JGH $10.36
- AMRN $7.08
- 52 Week High
- JGH $12.85
- AMRN $20.90
- Technical
- Relative Strength Index (RSI)
- JGH 30.07
- AMRN 34.89
- Support Level
- JGH $13.01
- AMRN $15.03
- Resistance Level
- JGH $13.15
- AMRN $15.85
- Average True Range (ATR)
- JGH 0.11
- AMRN 0.96
- MACD
- JGH -0.02
- AMRN -0.49
- Stochastic Oscillator
- JGH 16.98
- AMRN 10.73
About JGH Nuveen Global High Income Fund of Beneficial Interest
Nuveen Global High Income Fund operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of current income. Its securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.